6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
- Filed
- Period
- Accession number
- 0001213900-26-107425
Documents
- REPORT OF FOREIGN PRIVATE ISSUER 6-K
- PRESS RELEASE TITLED: "CLEARMIND ADVANCES DIALOGUE WITH U.S. FEDERAL GOVERNMENT ON PSYCHEDELIC THERAPIES, SUBMITTING RECOMMENDATIONS TO FDA" EX-99.1